Clinical Trial Update: A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate safety, tolerability, and pharmacokinetics after multiple doses of ABT-494 (upadacitinib) in healthy adults and adults with rheumatoid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Upadacitinib (ABT-494) (upadacitinib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED